Company Highlights:
Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.- The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments. The Company has taken the approach that, in order to have a truly successful drug that is accessible by all, numerous modifications need to be made to the first generation MDMA or Psilocybin molecules, most notably shortening the half-life while keeping the experience integrity intact.
- The Company is currently working with its pre-clinical team at the
University of Alberta to work these molecules through the Investigational New Drug enabling stage with the intent to put them into human clinical studies expected to commence in 2024. - The Company has a comprehensive intellectual property strategy covering novel molecules, drug formulations, delivery mechanisms, and methods of production. The Company believes this covers all described drug development activities in our named pipeline and clinical trials. The Company has filed these applications both in
the United States and through the Patent Cooperation Treaty (PCT) for protection in all jurisdictions in which the Company does business.
Management Commentary:
The Company will have a dual listing with its common shares fully fungible through a CREST Depositary Interest ("CDI"). The CDIs will carry the same ISIN as the Common Shares listed in
Sector Classification:
The Company is classified as a Healthcare company on the Access Segment of the
This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access. It has not been approved or reviewed by the
The Directors are of the opinion, having made due and careful enquiry, that the working capital available to the Company is sufficient for a period of at least twelve months following admission.
The Directors of Mydecine take responsibility for this announcement.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of
Learn more at https://www.mydecine.com.
For more information, please contact:
Media Contact pr@mydecineinc.com
Investor Relations investorrelations@mydecineinc.com
On behalf of the Board of Directors
contact@mydecineinc.com
AQSE Corporate Advisor
Novum Securities Limited Tel: +44 (0)207 399 9400
For further information about
About
Directors:
Robert is Chief Science Officer of Mydecine bringing his diverse background in biology, biotechnology, policy and intellectual property to innovation in the mycology space. Robert’s substantial expertise includes genetic engineering, molecular biology, bioinformatics, plant breeding and tissue culture, photomicroscopy, unicellular microinjection, fish husbandry and breeding colony maintenance and
transfection.
Following academic work studying the genetic dynamics of cellular patterning, Robert applied his advanced knowledge to cannabis plant enhancement. He joined ebbu in 2015, where he created IP related to the commercial optimisation of Cannabis sativa, industrial hemp and hops, resulting in three pending US patents.
In 2019 Rob oversaw the design, build and staffing of a plant analytical chemistry laboratory in
Neil is an experienced executive and thought leader in the technology community. He has a track record of driving growth, success and innovation and has worked in both corporate and entrepreneurial environments. For the past 15 years he has founded, led, and advised companies in consumer focused and medical tech industries including
Forward-looking Information
This news release contains forward-looking information about Canadian securities laws regarding the Company and its business. It relates to future events or performance and reflects management’s expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect,” “intends,” “anticipated,” “believes,” or variations (including negative variations) of such words and phrases or by stating that specific actions, events, or results “may,” "could," "would,” or “will” be taken, occur, or be achieved.
Such forward-looking statements reflect management’s beliefs and are based on assumptions and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to protect and enforce its intellectual property adequately, the Company's ability to bring its products to commercial production, the continued growth of the global adaptive pathway medicine, natural health products, and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale, and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause effects not to be as anticipated, estimated, or intended. There can be no assurance that such information will be accurate, as actual results and future events could differ materially from those anticipated. These forward-looking statements are made as of the date hereof. The Company is not obligated to update or revise them to reflect new events or circumstances as required under applicable securities legislation.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in
Suite 810–789 West
© OMX, source